comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 20:19:41 - browse：58725

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Malaysia cuts short music fest after British band slams anti

WSS

4 missing after record

How to bring more disabled researchers into academia

What Henrietta Lacks's story taught me about my role as a doctor

The drug industry has found itself all alone in Washington

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Burning questions about Delta and the next phase of the Covid pandemic

entertainment

comprehensive

leisure time

Virginia high school admissions case could be legal follow

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How to protect coverage of PrEP

Peter Hotez and the public health issue of online harassment

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

At least 13 dead in Texas as scorching temps continue

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Novavax promises a turnaround & Lilly roils the obesity market

FDA approves first blood sugar monitor without finger pricks

hotspot

A deep dive into Applied Therapeutics’ data, and questions on Cassava

The problem with charging patients to message their doctors

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Novartis develops a rapidly manufactured CAR

Novo Nordisk obesity pill bests Wegovy in early trial

Amylyx ALS drug failure raises questions and concerns

focus

hotspot

entertainment

knowledge